{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:26:33Z","timestamp":1787030793638,"version":"build-2736575974"},"reference-count":16,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Intravesical oxybutynin (IVO) is a 2nd line treatment option for patients with neurogenic detrusor overactivity (NDO) who are not adequately managed by oral anticholinergics. The UPSIDE study aimed to identify urodynamic and anamnestic predictors for achieving a therapeutically satisfactory dose (TSD) of 1\u2009mg\/mL IVO and to evaluate treatment outcomes including continence, quality of life (QoL), adherence, and handling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>UPSIDE was a prospective, multicentre, non\u2010interventional, real\u2010world study including paediatric (age\u2009\u2265\u20096) and adult patients with NDO due to spinal cord injury (SCI), spina bifida (SB), or multiple sclerosis (MS). Patients switched to IVO (VESOXX) were observed for at least 3 months. The primary endpoint was achievement of a TSD. Secondary endpoints included urodynamic changes, continence, spontaneous micturition, catheter volume, urinary tract infections (UTI), QoL (SF\u2010Qualiveen\u2010questionnaire), adherence, persistence, handling, pre\u2010 and concomitant therapies and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 54 patients enrolled across 14 study centres, 36 formed the full analysis set, and 26 (72%) were categorized with a TSD. Older age and reduced estimated glomerular filtration rate (eGFR) were identified as predictors for TSD (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.059;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011, respectively). A dose adaptation was necessary for almost every second patient (47.2%). Urodynamic parameters such as\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>det\u2009max<\/jats:sub>\n                      and bladder compliance improved. Maximal catheter volume increased significantly from 304 to 409\u2009mL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). Continence rates doubled (28% to 53%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043), spontaneous micturition increased from 33% to 42% (observed exclusively in patients with MS), daily micturition frequency decreased statistically significant from 8.3 to 4.6 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914 respectively). UTIs decreased from 42% to 25%. SF\u2010Qualiveen improved statistically significant by 25% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). 70% of patients rated handling of the prefilled syringe as easy or very easy. Adherence and persistence exceeded 80%. No therapy\u2010related serious adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VESOXX was effective in improving urodynamic parameters, continence, QoL, reduction of UTI and handling experience in NDO patients, with high adherence and no therapy\u2010related serious adverse events. TSD prediction is associated with older age and reduced eGFR. UPSIDE provides clinically relevant guidance for individualized intravesical therapy; however, interpretation of pressure\u2010based safety targets should remain cautious within the context of this pragmatic real\u2010world study.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      The UPSIDE non\u2010interventional trial is registered in the German clinical study registry DRKS under the number: DRKS00028775.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.70329","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:59:48Z","timestamp":1782194388000},"page":"1319-1327","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9982-4637","authenticated-orcid":false,"given":"Arndt","family":"Van Ophoven","sequence":"first","affiliation":[{"name":"Marien Hospital Herne Universit\u00e4tsklinikum der Ruhr\u2010Universit\u00e4t Herne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Banek","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts Medizin Frankfurt Klinik f\u00fcr Urologie Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0702-2640","authenticated-orcid":false,"given":"Kristin","family":"Becker","sequence":"additional","affiliation":[{"name":"Haunersches Kinderspital Kinderchirurgische Klinik und Poliklinik M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Heibel","sequence":"additional","affiliation":[{"name":"Sauerlandklinik Hachen gGmbH Sundern Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Klinik Hallerwiese\u2010Cnopfsche Kinderklinik Kinderneurologie N\u00fcrnberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8429-0951","authenticated-orcid":false,"given":"Margot","family":"Kieruj","sequence":"additional","affiliation":[{"name":"DRK Kamillus Klinik Asbach Asbach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-3780","authenticated-orcid":false,"given":"Ines","family":"Kurze","sequence":"additional","affiliation":[{"name":"Querschnittgel\u00e4hmten\u2010Zentrum\/Klinik f\u00fcr Paraplegiologie und Neuro\u2010UrologieBad Berka Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6123-4861","authenticated-orcid":false,"given":"Anja","family":"Lingnau","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin Klinik f\u00fcr Urologie, Kinderurologie Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-6108","authenticated-orcid":false,"given":"Barbara","family":"Ludwikowski","sequence":"additional","affiliation":[{"name":"Auf der Bult Kinder\u2010 und Jugendkrankenhaus Kinderchirurgie\/Kinderurologie Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-1539","authenticated-orcid":false,"given":"Tobias","family":"Luithle","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum T\u00fcbingen Kinderchirurgie und Kinderurologie T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2486-2740","authenticated-orcid":false,"given":"Fabian","family":"Queissert","sequence":"additional","affiliation":[{"name":"Kontinenz\u2010 und Beckenbodenzentrum in der Klinik f\u00fcr Urologie am UKM (Universit\u00e4tsklinikum M\u00fcnster) M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"R\u00f6sch","sequence":"additional","affiliation":[{"name":"KUNO Klinik St. Hedwig, Kinderurologie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schindler","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Ulm, Urologie und Kinderurologie Neuro\u2010Urologie Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-578X","authenticated-orcid":false,"given":"Regina","family":"Stredele","sequence":"additional","affiliation":[{"name":"LMU, Urologische Klinik und Poliklinik M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-9259","authenticated-orcid":false,"given":"Thomas Michael Karl","family":"V\u00f6lkl","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine KJF Klinik Josefinum Augsburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5599-0224","authenticated-orcid":false,"given":"Quentin","family":"Leidl","sequence":"additional","affiliation":[{"name":"Farco Pharma GmbH K\u00f6ln Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9305-732X","authenticated-orcid":false,"given":"Michael","family":"Gedamke","sequence":"additional","affiliation":[{"name":"Farco Pharma GmbH K\u00f6ln Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22755"},{"key":"e_1_2_12_3_1","unstructured":"Farco Pharma GmbH. VESOXX Fachinformation Deutschland. Published online March 2025 accessed August 18 2025 https:\/\/www.fachinfo.de\/fi\/detail\/023111\/vesoxx-1-mg-ml-loesung-zur-intravesikalen-anwendung."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.08.016"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23501"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10066"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3100995"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-022-01950-0"},{"key":"e_1_2_12_9_1","unstructured":"Y. B.Kalke H. T.Ho H. T.Ho et al. Intravesical Oxybutynin Treatment for Neurogenic Detrusor Overactivity: Efficacy and Safety Data from Clinical Practice with the First Intravesical Oxybutynin Treatment Authorized in Germany\u2014Beyond the Abstract.2023 https:\/\/doi.org\/10.3205\/23dkg31."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23017"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25604"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05924-6"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3100509"},{"issue":"4","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double\u2010blind, Placebo\u2010controlled Trial","volume":"60","author":"Cruz F.","year":"2011","journal-title":"European Urology"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21146"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62703-4"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.70329","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:55Z","timestamp":1787027035000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/nau.70329"],"URL":"https:\/\/doi.org\/10.1002\/nau.70329","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"2026-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}